Key players in Anti-Nerve Growth Factor
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 |  Pfizer Inc. |
pfizer.com (opens in a new tab) | 2,310 reports |
| 2 |  Regeneron Pharmaceuticals |
regeneron.com (opens in a new tab) | 429 reports |
| 3 |  Teva Pharmaceutical |
tevapharm.com (opens in a new tab) | 462 reports |
| 4 |  Sanofi |
sanofi.com (opens in a new tab) | 1,386 reports |
| 5 | Mitsubishi Tanabe Pharma Corporation | — | 66 reports |
| 6 |  Merck KGaA |
merckgroup.com (opens in a new tab) | 297 reports |
| 7 | Astellas Pharma Inc. | — | 264 reports |
Anti-Nerve Growth Factor reports by place
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
PhilippinesGet the full Anti-Nerve Growth Factor report
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.